世茂(00813.HK)股價曾飆25% 據報與萬科(02202.HK)洽談資產處置
《REDD》引述消息報道,萬科(02202.HK)與世茂(00813.HK)近期正在洽談資產處置。世茂股價午後飆升,一度飆25.7%高見5.91元,最新報5.71元,漲21.5%,成交近1.3億股,涉資6.8億元。
至於世茂債價亦跟升,《彭博》數據顯示,世茂7月份到期的美元債每1美元面值買價上漲3美仙,至47.6美仙。另在上海上市的世茂股份(600823.SH)漲停。
部分內房股亦炒高,融創中國(01918.HK)及中國奧園(03883.HK)齊漲逾13%,雅居樂(03383.HK)升10%,萬科升近3%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.